Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Cash from Financing Activities (2018 - 2025)

Serina Therapeutics' Cash from Financing Activities history spans 8 years, with the latest figure at $6.4 million for Q3 2025.

  • For Q3 2025, Cash from Financing Activities rose 7393.02% year-over-year to $6.4 million; the TTM value through Sep 2025 reached $22.0 million, up 168.88%, while the annual FY2024 figure was $13.2 million, 31.24% up from the prior year.
  • Cash from Financing Activities for Q3 2025 was $6.4 million at Serina Therapeutics, up from $5.6 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $10.1 million in Q1 2023 and bottomed at -$13000.0 in Q4 2023.
  • The 5-year median for Cash from Financing Activities is $2.0 million (2021), against an average of $2.8 million.
  • The largest annual shift saw Cash from Financing Activities plummeted 100.87% in 2023 before it surged 48890.91% in 2024.
  • A 5-year view of Cash from Financing Activities shows it stood at $1.5 million in 2021, then changed by 0.0% to $1.5 million in 2022, then tumbled by 100.87% to -$13000.0 in 2023, then skyrocketed by 38800.0% to $5.0 million in 2024, then grew by 28.09% to $6.4 million in 2025.
  • Per Business Quant, the three most recent readings for SER's Cash from Financing Activities are $6.4 million (Q3 2025), $5.6 million (Q2 2025), and $4.9 million (Q1 2025).